AnaptysBio Touts Positive Top-Line Phase III Data for Pustular Psoriasis Candidate

2023-10-13

临床结果临床3期免疫疗法

Pictured: Researchers in lab/Getty Images AnaptysBio has announced results from its Phase III GEMINI-1 trial, showing that the lgG4 antibody imsidolimab achieved its main goal in patients with a rare skin disorder linked to generalized pustular psoriasis. Imsidolimab is an IgG4 antibody that inhibits the function of the interleukin-36 receptor (IL-36R), a signaling pathway within the immune system involved in the pathogenesis of inflammatory diseases, such as generalized pustular psoriasis (GPP). The condition also covers large areas of the body and causes fever, shivers, intense itching and joint pain. The topline data showed that the registration trial reached the primary endpoint at week 4 after a single dose of imsidolimab, demonstrated by the clearing of pus-filled blisters in patients. In the study, 53.3% of patients who received a single dose of 750mg IV imsidolimab achieved GPPPGA 0/1 (clear or almost clear) at week four (primary endpoint), compared to 13.3% of patients on placebo. In addition, the drug showed favorable safety in patients without any serious adverse events reported. “GPP is an unpredictable and potentially life-threatening skin disease with systemic symptoms,” Hervé Bachelez, a professor of dermatology at the Hôpital Saint-Louis in Paris, said in a statement. “Achieving positive top-line results utilizing the GPPPGA composite endpoint in this well conducted, randomized controlled, global trial, along with a compelling safety profile, represents the potential for a single dose of imsidolimab to predictably provide relief for patients living with this burdensome disease.” The trial featured 45 randomized patients—15 per arm—that received either a single intravenous dose of anti-IL-36R antibody imsidolimab or placebo. The placebo patients who were worsening or not improved after day eight were eligible for rescue therapy and crossover into the GEMINI-2 Phase III trial, thus able to receive a single infusion of 750mg IV imsidolimab. Four weeks later, 53.3% of patients on the drug had a score of clear or almost clear, as measured on a physician assessment scale. AnaptysBio intends to submit marketing application for the drug to the FDA by the third quarter of 2024. “We intend to out-license imsidolimab with this compelling and competitive dataset to bring this therapy to patients living with this highly morbid condition and reallocate the potential proceeds of a transaction to further invest in the broad development of our best-in-class immune cell modulators, including our checkpoint agonists, in autoimmune and inflammatory diseases,” AnaptysBio CEO Daniel Faga said in a statement. Matt Olszewski is a freelance writer based in Boston. Reach him on LinkedIn.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构